Fortress Biotech (FBIO) Revenue & Revenue Breakdown

OverviewOwnership Financials Chart

Fortress Biotech Revenue Highlights

Latest Revenue (Y)

$59.66M

Latest Revenue (Q)

$14.63M

Main Segment (Y)

Qbrexza

Fortress Biotech Revenue by Period

Fortress Biotech Revenue by Year

Date	Revenue	Change
2023-12-31	$59.66M	-21.23%
2022-12-31	$75.74M	10.11%
2021-12-31	$68.79M	50.86%
2020-12-31	$45.60M	24.49%
2019-12-31	$36.63M	36.26%
2018-12-31	$26.88M	-85.67%
2017-12-31	$187.58M	1038.25%
2016-12-31	$16.48M	1809.62%
2015-12-31	$863.00K	100.00%
2014-12-31	-	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2011-12-31	-	100.00%
2010-12-31	-	-

Fortress Biotech generated $59.66M in revenue during NA 2023, up -21.23% compared to the previous quarter, and up 221.94% compared to the same period a year ago.

Fortress Biotech Revenue by Quarter

Date	Revenue	Change
2024-09-30	$14.63M	-1.79%
2024-06-30	$14.90M	14.32%
2024-03-31	$13.03M	-34.67%
2023-12-31	$19.95M	-42.60%
2023-09-30	$34.75M	99.88%
2023-06-30	$17.39M	39.88%
2023-03-31	$12.43M	-24.23%
2022-12-31	$16.40M	-0.75%
2022-09-30	$16.53M	-12.49%
2022-06-30	$18.89M	-21.06%
2022-03-31	$23.93M	30.91%
2021-12-31	$18.28M	-13.32%
2021-09-30	$21.09M	18.17%
2021-06-30	$17.84M	53.99%
2021-03-31	$11.59M	-15.72%
2020-12-31	$13.75M	45.11%
2020-09-30	$9.47M	0.19%
2020-06-30	$9.46M	-26.79%
2020-03-31	$12.92M	16.06%
2019-12-31	$11.13M	13.90%
2019-09-30	$9.77M	5.64%
2019-06-30	$9.25M	42.81%
2019-03-31	$6.48M	-104.15%
2018-12-31	$-156.07M	-345.03%
2018-09-30	$63.69M	-0.22%
2018-06-30	$63.83M	15.17%
2018-03-31	$55.42M	22.30%
2017-12-31	$45.32M	-3.34%
2017-09-30	$46.89M	-7.52%
2017-06-30	$50.70M	13.46%
2017-03-31	$44.68M	254.20%
2016-12-31	$12.62M	1193.85%
2016-09-30	$975.00K	-56.28%
2016-06-30	$2.23M	237.88%
2016-03-31	$660.00K	95.27%
2015-12-31	$338.00K	1252.00%
2015-09-30	$25.00K	100.00%
2015-06-30	-	-100.00%
2015-03-31	$500.00K	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	100.00%
2012-06-30	-	100.00%
2012-03-31	-	100.00%
2011-12-31	-	100.00%
2011-09-30	-	100.00%
2011-06-30	-	100.00%
2011-03-31	-	100.00%
2010-12-31	-	100.00%
2010-09-30	-	-

Fortress Biotech generated $14.63M in revenue during Q3 2024, up -1.79% compared to the previous quarter, and up 84.14% compared to the same period a year ago.

Fortress Biotech Revenue Breakdown

Fortress Biotech Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Zilxi	$1.96M	$2.27M	-	-	-
Accutane	$20.17M	$18.37M	$10.05M	-	-
Amzeeq	$6.20M	$7.24M	-	-	-
Exelderm	$2.40M	$3.46M	$5.36M	-	-
Qbrexza	$25.41M	$26.71M	$17.06M	-	-
Targadox	$3.20M	$7.97M	$22.38M	$28.07M	-
Ximino	$287.00K	$4.96M	$8.25M	$3.60M	-
Other Branded Revenue	-	-	$37.00K	$6.85M	-
Pharmaceutical And Biotechnology Product Development	-	-	-	$1.07M	-
Dermatology Products Sales	-	-	-	$44.53M	-
Return Reserve	-	-	-	-	$2.90M
License And Service	-	-	-	-	$1.70M
Royalty	-	-	-	-	$100.00K

Fortress Biotech's latest annual revenue breakdown by segment (product or service), as of Dec 23: Qbrexza (42.61%), Accutane (33.82%), Amzeeq (10.40%), Targadox (5.37%), Exelderm (4.02%), Zilxi (3.29%), and Ximino (0.48%).

Quarterly Revenue by Product

Product/Service	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Qbrexza	$6.84M	$5.02M	$21.32M	$4.09M	$6.96M	$6.26M	$6.11M	$7.38M	-	-	-	-	-	-	-	-	-	-	-	-
Accutane	$5.72M	$5.82M	$15.52M	$4.65M	$4.14M	$4.12M	$5.20M	$4.91M	-	-	-	-	-	-	-	-	-	-	-	-
Zilxi	$369.00K	$273.00K	$1.65M	$314.00K	$422.00K	$554.00K	$555.00K	$741.00K	-	-	-	-	-	-	-	-	-	-	-	-
Amzeeq	$1.21M	$755.00K	$5.01M	$1.19M	$1.35M	$1.16M	$1.26M	$3.47M	-	-	-	-	-	-	-	-	-	-	-	-
Ximino	-	-	-	$612.00K	$1.18M	$1.77M	$1.03M	$967.00K	$1.41M	$2.19M	-	-	-	-	-	-	-	-	-	-
Exelderm	-	-	$1.88M	$511.00K	$445.00K	$1.00M	$1.31M	$704.00K	$668.00K	-	-	-	-	-	-	-	-	-	-	-
Targadox	-	-	$2.41M	$793.00K	$1.41M	$1.17M	$2.76M	$2.63M	$8.53M	$6.61M	$7.23M	$5.70M	-	-	-	-	-	-	-	-
Other Branded Revenue	-	-	-	-	-	-	-	$1.00K	$6.48M	$22.00K	-	-	-	-	-	-	-	-	-	-
Dermatology Products Sales	-	-	-	-	-	-	-	-	$17.52M	$19.61M	$15.29M	$10.72M	$13.72M	$9.45M	$9.41M	$11.95M	-	-	-	-
Pharmaceutical and Biotechnology Product Development	-	-	-	-	-	-	-	-	$759.00K	-	-	-	-	-	-	-	-	-	-	-
Pharmaceutical And Biotechnology Product Development	-	-	-	-	-	-	-	-	-	$1.48M	$2.56M	$868.00K	$26.00K	$28.00K	$42.00K	$972.00K	-	-	-	-
Consolidated	-	-	-	-	-	-	-	-	-	-	-	-	-	$9.47M	$9.46M	$12.92M	-	-	-	-

Fortress Biotech's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Qbrexza (48.38%), Accutane (40.48%), Amzeeq (8.53%), and Zilxi (2.61%).

Fortress Biotech Revenue Breakdown by Country

Quarterly Revenue by Country

Country	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18
Accutane	$4.65M	$4.14M	$4.12M	$5.20M	$4.91M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exelderm	$511.00K	$445.00K	$1.00M	$1.31M	$704.00K	$668.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Qbrexza	$4.09M	$6.96M	$6.26M	$6.11M	$7.38M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Targadox	$793.00K	$1.41M	$1.17M	$2.76M	$2.63M	$8.53M	$6.61M	$7.23M	$5.70M	$5.04M	$4.32M	$6.36M	-	-	-	-	-	-	-	-
Ximino	$612.00K	$1.18M	$1.77M	$1.03M	$967.00K	$1.41M	$2.19M	-	-	-	-	-	-	-	-	-	-	-	-	-
Zilxi	$314.00K	$422.00K	$554.00K	$555.00K	$741.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amzeeq	$1.19M	$1.35M	$1.16M	$1.26M	$3.47M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Branded Revenue	-	-	-	-	$1.00K	$6.48M	$22.00K	$968.00K	-	-	-	-	-	-	-	-	-	-	-	-
Dermatology Products Sales	-	-	-	-	-	$17.52M	$19.61M	$15.29M	$10.72M	$13.72M	$9.45M	$9.41M	$11.95M	-	-	-	-	-	-	-
Pharmaceutical and Biotechnology Product Development	-	-	-	-	-	$759.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pharmaceutical And Biotechnology Product Development	-	-	-	-	-	-	$1.48M	$2.56M	$868.00K	$26.00K	$28.00K	$42.00K	$972.00K	-	-	-	-	-	-	-
Consolidated	-	-	-	-	-	-	-	-	-	-	$9.47M	$9.46M	$12.92M	-	-	-	-	-	-	-
License and Service	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.10M	-	-
Other branded revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$846.00K	$326.00K

Fortress Biotech's latest quarterly revenue breakdown by geography, as of Mar 23: Accutane (38.21%), Qbrexza (33.65%), Amzeeq (9.81%), Targadox (6.52%), Ximino (5.03%), Exelderm (4.20%), and Zilxi (2.58%).

Fortress Biotech Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ACAD	ACADIA Pharmaceuticals	$726.44M	$250.40M
FBIO	Fortress Biotech	$59.66M	$14.63M
PIRS	Pieris Pharmaceuticals	$42.81M	-
LUMO	Lumos Pharma	$2.05M	$488.00K
CKPT	Checkpoint Therapeutics	$103.00K	-
EYEN	Eyenovia	$3.79K	$1.63K
APTO	Aptose Biosciences	-	-
MBIO	Mustang Bio	-	-
CABA	Cabaletta Bio	-	-
RVPH	Reviva Pharmaceuticals	-	-
ALRN	Aileron Therapeutics	-	-
ATHA	Athira Pharma	-	-
CGTX	Cognition Therapeutics	-	-
ACHL	Achilles Therapeutics	-	-
ATXI	Avenue Therapeutics	-	-
KOD	Kodiak Sciences	-	-
RNAZ	TransCode Therapeutics	-	-

FBIO Revenue FAQ

What is Fortress Biotech’s yearly revenue?

Fortress Biotech's yearly revenue for 2023 was $59.66M, representing a decrease of -21.23% compared to 2022. The company's yearly revenue for 2022 was $75.74M, representing an increase of 10.11% compared to 2021. FBIO's yearly revenue for 2021 was $68.79M, representing an increase of 50.86% compared to 2020.

What is Fortress Biotech’s quarterly revenue?

Fortress Biotech's quarterly revenue for Q3 2024 was $14.63M, a -1.79% decrease from the previous quarter (Q2 2024), and a -57.90% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $14.9M, a 14.32% increase from the previous quarter (Q1 2024), and a -14.32% decrease year-over-year (Q2 2023). FBIO's quarterly revenue for Q1 2024 was $13.03M, a -34.67% decrease from the previous quarter (Q4 2023), and a 4.84% increase year-over-year (Q1 2023).

What is Fortress Biotech’s revenue growth rate?

Fortress Biotech's revenue growth rate for the last 3 years (2021-2023) was -13.27%, and for the last 5 years (2019-2023) was 62.88%.

What are Fortress Biotech’s revenue streams?

Fortress Biotech's revenue streams in c 23 are Zilxi, Accutane, Amzeeq, Exelderm, Qbrexza, Targadox, and Ximino. Zilxi generated $1.96M in revenue, accounting 3.29% of the company's total revenue, down -13.68% year-over-year. Accutane generated $20.17M in revenue, accounting 33.82% of the company's total revenue, up 9.77% year-over-year. Amzeeq generated $6.2M in revenue, accounting 10.40% of the company's total revenue, down -14.37% year-over-year. Exelderm generated $2.4M in revenue, accounting 4.02% of the company's total revenue, down -30.84% year-over-year. Qbrexza generated $25.41M in revenue, accounting 42.61% of the company's total revenue, down -4.88% year-over-year. Targadox generated $3.2M in revenue, accounting 5.37% of the company's total revenue, down -59.81% year-over-year. Ximino generated $287K in revenue, accounting 0.48% of the company's total revenue, down -94.21% year-over-year.

What is Fortress Biotech’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Fortress Biotech was Qbrexza. This segment made a revenue of $25.41M, representing 42.61% of the company's total revenue.